50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,635.82 (-0.53%)
DOW   29,057.98 (-0.69%)
QQQ   273.05 (-0.48%)
AAPL   151.20 (+0.29%)
MSFT   235.36 (-0.88%)
META   134.90 (-1.08%)
GOOGL   97.17 (-1.02%)
AMZN   113.57 (-1.37%)
TSLA   279.10 (+1.12%)
NVDA   123.08 (+0.65%)
NIO   17.04 (-3.29%)
BABA   77.41 (-1.90%)
AMD   66.36 (+0.09%)
T   15.77 (+0.64%)
MU   49.77 (+1.82%)
CGC   2.78 (+1.46%)
F   11.77 (-1.83%)
GE   63.77 (-0.90%)
DIS   96.29 (-1.87%)
AMC   7.06 (+3.37%)
PYPL   84.83 (+0.68%)
PFE   43.97 (+0.32%)
NFLX   222.01 (-0.92%)
S&P 500   3,635.82 (-0.53%)
DOW   29,057.98 (-0.69%)
QQQ   273.05 (-0.48%)
AAPL   151.20 (+0.29%)
MSFT   235.36 (-0.88%)
META   134.90 (-1.08%)
GOOGL   97.17 (-1.02%)
AMZN   113.57 (-1.37%)
TSLA   279.10 (+1.12%)
NVDA   123.08 (+0.65%)
NIO   17.04 (-3.29%)
BABA   77.41 (-1.90%)
AMD   66.36 (+0.09%)
T   15.77 (+0.64%)
MU   49.77 (+1.82%)
CGC   2.78 (+1.46%)
F   11.77 (-1.83%)
GE   63.77 (-0.90%)
DIS   96.29 (-1.87%)
AMC   7.06 (+3.37%)
PYPL   84.83 (+0.68%)
PFE   43.97 (+0.32%)
NFLX   222.01 (-0.92%)
S&P 500   3,635.82 (-0.53%)
DOW   29,057.98 (-0.69%)
QQQ   273.05 (-0.48%)
AAPL   151.20 (+0.29%)
MSFT   235.36 (-0.88%)
META   134.90 (-1.08%)
GOOGL   97.17 (-1.02%)
AMZN   113.57 (-1.37%)
TSLA   279.10 (+1.12%)
NVDA   123.08 (+0.65%)
NIO   17.04 (-3.29%)
BABA   77.41 (-1.90%)
AMD   66.36 (+0.09%)
T   15.77 (+0.64%)
MU   49.77 (+1.82%)
CGC   2.78 (+1.46%)
F   11.77 (-1.83%)
GE   63.77 (-0.90%)
DIS   96.29 (-1.87%)
AMC   7.06 (+3.37%)
PYPL   84.83 (+0.68%)
PFE   43.97 (+0.32%)
NFLX   222.01 (-0.92%)
S&P 500   3,635.82 (-0.53%)
DOW   29,057.98 (-0.69%)
QQQ   273.05 (-0.48%)
AAPL   151.20 (+0.29%)
MSFT   235.36 (-0.88%)
META   134.90 (-1.08%)
GOOGL   97.17 (-1.02%)
AMZN   113.57 (-1.37%)
TSLA   279.10 (+1.12%)
NVDA   123.08 (+0.65%)
NIO   17.04 (-3.29%)
BABA   77.41 (-1.90%)
AMD   66.36 (+0.09%)
T   15.77 (+0.64%)
MU   49.77 (+1.82%)
CGC   2.78 (+1.46%)
F   11.77 (-1.83%)
GE   63.77 (-0.90%)
DIS   96.29 (-1.87%)
AMC   7.06 (+3.37%)
PYPL   84.83 (+0.68%)
PFE   43.97 (+0.32%)
NFLX   222.01 (-0.92%)
NASDAQ:RGNX

REGENXBIO - RGNX Stock Forecast, Price & News

$22.72
+0.43 (+1.93%)
(As of 09/27/2022 01:14 PM ET)
Add
Compare
Today's Range
$22.64
$23.28
50-Day Range
$22.29
$35.04
52-Week Range
$18.69
$44.40
Volume
3,846 shs
Average Volume
331,995 shs
Market Capitalization
$982.19 million
P/E Ratio
11.77
Dividend Yield
N/A
Price Target
$43.86

REGENXBIO MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.71 Rating Score
Upside/​Downside
93.5% Upside
$43.86 Price Target
Short Interest
Healthy
8.03% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.82
Upright™ Environmental Score
News Sentiment
0.41mentions of REGENXBIO in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$277,579 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($5.23) to ($3.12) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.72 out of 5 stars

Medical Sector

102nd out of 1,071 stocks

Biological Products, Except Diagnostic Industry

14th out of 172 stocks

RGNX stock logo

About REGENXBIO (NASDAQ:RGNX) Stock

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.

Receive RGNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for REGENXBIO and its competitors with MarketBeat's FREE daily newsletter.

RGNX Stock News Headlines

What 4 Analyst Ratings Have To Say About Regenxbio
5 Biotechs With Cash Runways Into 2025 - TheStreet
See More Headlines
Receive RGNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for REGENXBIO and its competitors with MarketBeat's FREE daily newsletter.

RGNX Company Calendar

Last Earnings
8/03/2022
Today
9/27/2022
Next Earnings (Estimated)
11/01/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RGNX
Fax
N/A
Employees
372
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$43.86
High Stock Price Forecast
$76.00
Low Stock Price Forecast
$17.00
Forecasted Upside/Downside
+93.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
7 Analysts

Profitability

Net Income
$127.84 million
Pretax Margin
21.49%

Debt

Sales & Book Value

Annual Sales
$470.35 million
Cash Flow
$3.33 per share
Book Value
$17.87 per share

Miscellaneous

Free Float
37,740,000
Market Cap
$982.19 million
Optionable
Optionable
Beta
1.09

Key Executives

  • Mr. Kenneth T. MillsMr. Kenneth T. Mills (Age 47)
    Pres, CEO & Director
    Comp: $1.72M
  • Mr. Vittal K. Vasista (Age 54)
    Exec. VP & Chief Financial Officer
    Comp: $1.25M
  • Mr. Curran M. Simpson M.S. (Age 60)
    Exec. VP and Chief Operations & Technology Officer
    Comp: $924.95k
  • Dr. Olivier Danos Ph.D. (Age 64)
    Exec. VP & Chief Scientific Officer
    Comp: $842.08k
  • Mr. Patrick J. Christmas II (Age 51)
    J.D., Exec. VP & Chief Legal Officer
    Comp: $1.11M
  • Ms. Tricia Truehart
    VP of Investor Relations & Corp. Communications
  • Mr. Andrew Yost
    VP of Corp. Devel.
  • Ms. Shiva G. Fritsch
    Chief People Officer
  • Dr. Laura A. Coruzzi J.D. (Age 69)
    Ph.D., Sr. VP of Intellectual Property
  • Dr. Ram Palanki Pharm.D.
    Sr. VP of Commercial Strategy & Operations













RGNX Stock - Frequently Asked Questions

Should I buy or sell REGENXBIO stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for REGENXBIO in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RGNX shares.
View RGNX analyst ratings
or view top-rated stocks.

What is REGENXBIO's stock price forecast for 2022?

7 equities research analysts have issued twelve-month target prices for REGENXBIO's stock. Their RGNX share price forecasts range from $17.00 to $76.00. On average, they predict the company's share price to reach $43.86 in the next year. This suggests a possible upside of 96.8% from the stock's current price.
View analysts price targets for RGNX
or view top-rated stocks among Wall Street analysts.

How have RGNX shares performed in 2022?

REGENXBIO's stock was trading at $32.70 at the beginning of 2022. Since then, RGNX shares have decreased by 31.8% and is now trading at $22.29.
View the best growth stocks for 2022 here
.

When is REGENXBIO's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our RGNX earnings forecast
.

How were REGENXBIO's earnings last quarter?

REGENXBIO Inc. (NASDAQ:RGNX) posted its earnings results on Wednesday, August, 3rd. The biotechnology company reported ($1.58) EPS for the quarter, missing analysts' consensus estimates of ($1.44) by $0.14. The biotechnology company had revenue of $32.65 million for the quarter, compared to analyst estimates of $26 million. REGENXBIO had a trailing twelve-month return on equity of 15.40% and a net margin of 18.73%.

What is Ken Mills' approval rating as REGENXBIO's CEO?

3 employees have rated REGENXBIO Chief Executive Officer Ken Mills on Glassdoor.com. Ken Mills has an approval rating of 68% among the company's employees.

What other stocks do shareholders of REGENXBIO own?

Based on aggregate information from My MarketBeat watchlists, some companies that other REGENXBIO investors own include AbbVie (ABBV), Micron Technology (MU), NVIDIA (NVDA), Voyager Therapeutics (VYGR), Amarin (AMRN), CRISPR Therapeutics (CRSP), Pfizer (PFE), QUALCOMM (QCOM), Gilead Sciences (GILD) and Block (SQ).

What is REGENXBIO's stock symbol?

REGENXBIO trades on the NASDAQ under the ticker symbol "RGNX."

Who are REGENXBIO's major shareholders?

REGENXBIO's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include JPMorgan Chase & Co. (9.82%), State Street Corp (6.48%), Point72 Asset Management L.P. (1.31%), Goldman Sachs Group Inc. (1.16%), Northern Trust Corp (0.98%) and Principal Financial Group Inc. (0.60%). Insiders that own company stock include Allan M Fox, Curran Simpson, Donald J Hayden Jr, Kenneth T Mills, Kenneth T Mills, Patrick J Christmas, Steve Pakola, Vittal Vasista and WR Stephens, Iii 2012 Trust.
View institutional ownership trends
.

How do I buy shares of REGENXBIO?

Shares of RGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is REGENXBIO's stock price today?

One share of RGNX stock can currently be purchased for approximately $22.29.

How much money does REGENXBIO make?

REGENXBIO (NASDAQ:RGNX) has a market capitalization of $963.60 million and generates $470.35 million in revenue each year. The biotechnology company earns $127.84 million in net income (profit) each year or $1.93 on an earnings per share basis.

How many employees does REGENXBIO have?

The company employs 372 workers across the globe.

How can I contact REGENXBIO?

REGENXBIO's mailing address is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. The official website for the company is www.regenxbio.com. The biotechnology company can be reached via phone at (240) 552-8181 or via email at ir@regenxbio.com.

This page (NASDAQ:RGNX) was last updated on 9/27/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.